Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
419 studies found for:    "Fallopian tube cancer"
Show Display Options
Rank Status Study
21 Terminated Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Intervention:
22 Withdrawn Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Conditions: Fallopian Tube Cancer;   Fatigue;   Neuropathy;   Neurotoxicity;   Ovarian Cancer;   Pain;   Primary Peritoneal Cavity Cancer
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Other: placebo
23 Active, not recruiting TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
24 Terminated Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: gemcitabine hydrochloride;   Drug: topotecan hydrochloride
25 Withdrawn Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: gemcitabine hydrochloride
26 Active, not recruiting Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Breast Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: cyclophosphamide;   Biological: multi-epitope folate receptor alpha peptide vaccine;   Other: laboratory biomarker analysis
27 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Cisplatin;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
28 Completed
Has Results
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Conditions: Ovarian Cancer;   Peritoneal Primary Cancer;   Fallopian Tube Cancer
Interventions: Other: healing touch;   Other: massage therapy;   Other: hypnosis;   Drug: Standard chemotherapy
29 Completed AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Other: pharmacological study
30 Not yet recruiting Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: regorafenib
31 Recruiting Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: RAD001;   Drug: bevacizumab
32 Terminated
Has Results
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Serous Cancer;   Fallopian Tube Cancer
Intervention: Drug: bevacizumab
33 Completed VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: docetaxel;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis;   Other: pharmacological study
34 Recruiting Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: intravenous docetaxel with intraperitoneal oxaliplatin;   Drug: intravenous oxaliplatin with intraperitoneal docetaxel
35 Completed A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: rhuMAb 2C4 (pertuzumab)
36 Suspended A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention: Drug: D4064A
37 Active, not recruiting Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Intervention: Other: laboratory biomarker analysis
38 Recruiting Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Paclitaxel,;   Drug: Bevacizumab;   Drug: Cisplatin;   Drug: Olaparib
39 Recruiting A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
Conditions: Recurrent Ovarian Cancer,;   Fallopian Tube Cancer
Intervention: Drug: Intraoperative (hyperthermic) cisplatin followed by IP Cisplatin; Doxorubicin
40 Completed Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary PERITONEUM;   Fallopian Tube Cancer
Intervention: Drug: Paclitaxel,Cisplatin, Bevacizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years